Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice

Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice

J Drugs Dermatol. 2019 Feb 01;18(2):122-129

Authors: Lebwohl M, Alexis AF, Beck LA, Block JK, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Boguniewicz M

Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects around 13% of children and 7% of adults in the US. It can have a significant impact on the quality of life (QoL) of affected individuals due to pruritus and the visibility of lesions on the skin. AD is increasingly recognized as a systemic disease, since dysregulation of the adaptive and innate immune systems plays a key role in the underlying disease pathogenesis, which has important implications for how the condition is treated. Patients with moderate-to-severe disease who have failed to achieve disease control may benefit from systemic immunomodulatory treatments. Recently published expert perspectives outlined recommendations for the diagnosis and treatment of moderate-to-severe AD in adults, reflecting evidence-based, practical recommendations to support allergists and dermatologists in selecting appropriate treatment in the era of biologic therapies. To help clinicians understand how these practical recommendations can be implemented into clinical practice, we describe two real life case studies of adult patients with AD. In these case studies, we demonstrate how AD severity, treatment response, and treatment failure can be assessed, and the role of emerging systemic treatments in the management of moderate-to-severe AD. J Drugs Dermatol. 2019;18(2):122-129.

PMID: 30794360 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader https://ift.tt/2E8ZeL6